Lightning Round: I would buy M&T Bank tomorrow morning, says Jim Cramer

Stock Recommendations & Analysis - Pfizer: Good yield but lacks momentum, recent update was unfavorable, considered a weak hold [1] - Elanco: Impressed with the company's turnaround, a supplier to retail dealing with livestock and pets [2] - Rocket Lab: Considered a good speculative play, better than just magical thinking, ahead of another big offering [3][4] - LA lithium: Not recommended, considered a no-go [4] - Scoreboard company (unnamed): New CEO, CFO, and $30 price target, institutionally held by BlackRock, but the business is not compelling enough [5] - Thorance (unnamed): Needs further research, analyst ratings are all buy or strong buy with over 11% short position [6] - M&T Bank: Surprisingly inexpensive at 12 times earnings, recommended as a buy [9][10] - Unnamed company: Revenues are up 600% this year, sitting on $800 million cash, $3 billion market cap expects to be cash flow positive next year, viewed as a "cats and dog thing" and a pass [11] Industry Trends & Observations - Beer and liquor companies: Potentially negatively impacted by GLP1 drugs like Lily's [7] - Constellation and Brown-Forman: Downgraded, dividend yield at 5.6% may provide some support [8]